Phase II pilot trial of 'chemo-switch' regimen [vinblastine, cisplatin, interferon alpha, interleukin 2] of biochemotherapy followed by daily low-dose temozolomide plus sorafenib in advanced melanoma
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2016
At a glance
- Drugs Sorafenib (Primary) ; Cisplatin; Interferon alpha; Interleukin-2; Temozolomide; Vinblastine
- Indications Malignant melanoma
- Focus Therapeutic Use
- 20 Mar 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 31 May 2008 New trial record.